Advanced Semantic Knowledge-Based Bio-Medical Search Solution

A web browser that can understand technical terms in life sciences and automatically find additional resources and services has been developed by European researchers. It could lead to a new generation of intelligent search engines. The life sciences community has built numerous databases - such as for gene sequencing and information about diseases - that are available to researchers as 'grid' services.

"Grid computing is essentially about building virtual organisations that are independent of the physical location where they reside," says Michael Schroeder of Technische Universität Dresden.

The problem is how to link those services to other scientific information found on the web. Schroeder is coordinator of the EU-funded Sealife project which has created a 'semantic grid browser' to make grid services for the life sciences much more accessible.

"We have the web on the one hand and then we have grid computing, with its many services, on the other," he says. "A semantic grid browser seamlessly integrates them.

"It tries to understand what it finds on web pages, interprets this content and then links it, on the fly, to services that might be useful to the user."

The key to the Sealife browser is a 'semantic hyperlink' that shows up on the page to direct users to relevant services. The link is not put there by the website but by the browser itself.

How does it do that?
First, the browser needs to understand the content of the page and identify terms which could be linked to grid services. An example tested in the Sealife project is the naming of genes. Each human gene has an average of 5.5 names, Schroeder points out, but if it can be identified correctly, a link can be made to a wealth of information about that gene.

The browser must also be able to handle ambiguity. "If I see 'Jaguar' on a web page, what is it? Is it an animal? Is it a car? Is it the Mac operating system?" Sealife uses specialised algorithms to work out the context from other words on the page and correctly interpret the meaning.

It is still not an exact science, though. The Sealife team entered their algorithm in an international competition with 50 others to identify names of genes. They won, with an 81% success rate, though Schroeder says they have now got that up to 87%.

Background knowledge
The second challenge is the background knowledge that allows the browser to make sense of the identified terms. Such knowledge is formally known as an 'ontology', a systematic hierarchy of concepts and their relation to one another. Biology, with its extensive taxonomies, is an ideal field for semantic grid browsing.

"All these efforts of building hierarchical classification systems have been at the core of biology for centuries," says Schroeder. "Biologists are used to it and there are many efforts to make information exchangeable."

But outside the life sciences such systematic classification is not so well developed, and the Sealife project has created editors to build ontologies from published literature in any specific field of interest.

"We developed algorithms that grind through this data, identify the key concepts and then the ontology editor offers these concepts to you," Schroeder explains. "If you agree, it then searches the web to find things that look like definitions. This whole process of building this background knowledge cannot be fully automated but you can ease the pain of doing this quite significantly."

Different varieties of the Sealife browser build on work by partners in Edinburgh, Manchester, London and Sophia-Antipolis, as well as in Dresden. They have been tested in three scenarios: evidence-based medicine, mining of scientific and patent literature, and in molecular biology. In each case, the focus has been on infectious diseases.

Browser that understands everything?
So successful has the project been that TU Dresden has spun-off a new company, Transinsight, to exploit work done in Sealife. The company has sold semantic browsers to such major customers as BASF and Unilever and runs the GoPubMed search engine, which is linked to the respected PubMed archive of biomedical literature.

But there is no reason why a semantic browser should be confined to specialised academic areas. Could we have a browser that understands everything? Schroeder thinks that is not as far-fetched as it may seem. "The vision is to include every domain," he says. "For example, if we were able to extract and formalise the knowledge in Wikipedia we would have this general background knowledge that covers all areas."

Many researchers look forward to a next-generation search engine that can understand what the user is looking for and return much more relevant results than today's engines can. "This will involve integrating information," says Schroeder, "because very often answers to questions are not provided in one document as a single statement that I can pick up by keywords.

"In the future, we will need background knowledge and this is at the core of Sealife. If we build semantic into search, and make it scaleable, then you will have the next-generation search engine."

The Sealife project received funding from the ICT strand of the EU's Sixth Framework Programme for research.

For further infoprmation, please visit:

Source: ICT Results

About Transinsight
Transinsight is focused on semantic software solutions in the area of knowledge- and meaning-based computing. The flagship product, GoPubMed PRO, a semantic biomedical search engine, is the first knowledge-based search engine for the Life Sciences on the Internet. The enterprise is headquartered in Dresden, Germany. Transinsight is ranked under the Top 5 biotech companies in Europe.

Most Popular Now

FDA approves drug to treat ALS

The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...

Read more

FDA approves first cancer treatment for any solid …

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is th...

Read more

Sanofi and Regeneron announce FDA Approval of Kevz…

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients...

Read more

AstraZeneca marks a key milestone with the ‘toppin…

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate ...

Read more

FDA approves first treatment for a form of Batten …

The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved ...

Read more

Abbott announces CE Mark and first use of the worl…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will h...

Read more

Imfinzi significantly reduces the risk of disease …

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blind...

Read more

Antibiotic doxycycline may offer hope for treatmen…

A study published in the journal Scientific Reports suggests that doxycycline, an antibiotic used for over half a century against bacterial infections, can be prescribed ...

Read more

Novartis exercises exclusive option agreement with…

Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercia...

Read more

England's Cancer Drugs Fund 'failed to deliver mea…

Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may...

Read more

High levels of exercise linked to nine years of le…

Despite their best efforts, no scientist has ever come close to stopping humans from aging. Even anti-aging creams can't stop Old Father Time. But new research from Brigh...

Read more

Vitamin A deficiency is detrimental to blood stem …

Many specialized cells, such as in the skin, gut or blood, have a lifespan of only a few days. Therefore, steady replenishment of these cells is indispensable. They arise...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]